Search clinical trials for: Mucopolysaccharidosis (mps) 2

Total 47781 results

University of Melbourne
Alcon Research; Clinical Vision Research Australia

Completed

Time Course Comparison of Contact Lens Maintenance Systems for Hydrogel Lenses

Myopia | Hyperopia

Australia
University of Minnesota
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Completed

Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network

Mucopolysaccharidoses

United States
Abbott Medical Optics

Completed

Comparative Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions

Astigmatism | Myopia | Hyperopia

United States
Mackay Memorial Hospital
Sanofi Taiwan Co. Ltd

Recruiting

The Intensively Follow-up Examinations for Asymptomatic MPS I Infants in Taiwan

MPS I

Taiwan
Institut National de la Santé Et de la Recherche...

Recruiting

MPS (RaDiCo Cohort) (RaDiCo-MPS)

Mucopolysaccharidosis I | Mucopolysaccharidosis II | Mucopolysaccharidosis VI | Mucopolysaccharidosis III | Mucopolysaccharidosis IV | Mucopolysaccharidosis VII | Multiple Sulfatase Deficiency Disease | Mucopolysaccharidosis IX

France
Poitiers University Hospital

Completed

Relationships Between Macular Pigment Optical Density and Lacquer Cracks in High Myopic Patients.

High Myopia

France
Assistance Publique - Hôpitaux de Paris

Terminated

Magnetic Resonance Diabetic Cardiac Stress Imaging (MRDiabetics)

Coronary Insufficiency

France
Abbott Medical Optics

Completed

Short-Term Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions

Corneal Staining

United States
University of Minnesota
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Completed

MRS to Determine Neuroinflammation and Oxidative Stress in MPS I

Mucopolysaccharidosis Type I

United States
National MPS Society
MediResource Inc.

Terminated

Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics

Mucopolysaccharidosis I | Mucopolysaccharidosis II | Mucopolysaccharidoses | Mucopolysaccharidosis VI | Mucopolysaccharidosis IV

United States
Immusoft of CA, Inc.

Recruiting

ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I

Mucopolysaccharidosis IH/S | Mucopolysaccharidosis IS

United States
Shire

Completed

A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®

Hunter Syndrome

United States, United Kingdom
Shire

Completed

Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)

Sanfilippo Syndrome Type B

United States, United Kingdom, Germany
Abbott Medical Optics

Withdrawn

Complete Easy Rub Comparative Efficacy Study

Astigmatism | Myopia | Hyperopia
University of California, San Francisco
Duke University

Recruiting

In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases (IUERT)

Wolman Disease | MPS IVA | Pompe Disease Infantile-Onset | Gaucher Disease, Type 2 | MPS VI | MPS I | Gaucher Disease, Type 3 | MPS II | Mps VII

United States
Innovative Medical

Completed

Comfort Evaluation of a New MPS vs. Replenish in Contact Lens Patients

Corneal Staining

United States
UCB Pharma

Completed

An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)

Postherpetic Neuralgia

Germany
UCB Pharma

Completed

A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy

Diabetic Neuropathy

United States
UCB Pharma

Completed

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

Partial Seizures With or Without Secondary Generalization

Germany
UCB Pharma

Completed

SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

Epilepsy
Shire

Completed

Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)

Mucopolysaccharidosis II

United States, United Kingdom, Brazil, Germany
University of North Carolina, Chapel Hill
Metagenics, Inc.; North Carolina Translational and Clinical Sciences Institute

Completed

Bioavailability of SPMs in Obese Humans

Obesity Adult Onset

United States
UCB Pharma

Completed

Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy

Diabetic Neuropathies

United States
UCB Pharma

Completed

Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

Epilepsies, Partial

United States
Lundquist Institute for Biomedical Innovation at...

Terminated

Clinical Trial of Growth Hormone in MPS I, II, and VI

Mucopolysaccharidosis I | Mucopolysaccharidosis II | Mucopolysaccharidosis VI

United States
Zimmer Biomet

Recruiting

PMCF Study of MPS-Flex® Knee System in TKA

Total Knee Arthroplasty

China
Seoul National University Bundang Hospital

Completed

Mobile App for BP Control (SMART-BP)

Hypertension

Korea, Republic of
Genzyme, a Sanofi Company
BioMarin/Genzyme LLC

Completed

Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease

Mucopolysaccharidosis I | Scheie Syndrome | Hurler Syndrome | Hurler-Scheie Syndrome

Japan
ArmaGen, Inc

Completed

Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I

Mucopolysaccharidosis I

United States
Innovative Medical

Completed

Comfort and Cleaning Evaluation of Multipurpose Solutions in Contact Lens Patients

Patient Comfort | Lens Cleanliness

United States
Denali Therapeutics Inc.

Recruiting

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) (COMPASS)

Mucopolysaccharidosis II

United States, Spain, United Kingdom, Czechia, France, Canada, Italy, Belgium, Netherlands, Germany, Argentina, Sweden, Turkey, Colombia
Duke University

Recruiting

MPS II Immunophenotyping

Mucopolysaccharidosis II | Hunter Syndrome | MPS II

United States
Sigilon Therapeutics, Inc.

Withdrawn

Safety and Efficacy of Encapsulated Allogeneic MPS-1 Therapy

MPS I | MPS1-S | MPS1-HS

Brazil, United Kingdom
Nationwide Children's Hospital
Sanfilippo Children's Research Foundation; The Sanfilippo Research Foundation; The Children's Medical Research Foundation

Completed

Natural History Studies of Mucopolysaccharidosis III

Mucopolysaccharidosis Type IIIA | Mucopolysaccharidosis Type IIIB

United States
Denali Therapeutics Inc.

Enrolling by invitation

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Mucopolysaccharidosis II

United States, Canada, Belgium, Czechia, Netherlands
Shire

Completed

Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase

Hunter Syndrome | Mucopolysaccharidosis II (MPS II)

United States, France, United Kingdom, Germany, Sweden, Spain, Brazil, Canada, Italy, Romania
Allievex Corporation

Active, not recruiting

A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)

Mucopolysaccharidosis Type IIIB

United States, Germany, Spain, Argentina, Australia, Brazil, Colombia, Taiwan, Turkey
Shire

Completed

An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients

Hunter Syndrome

United Kingdom, United States, Brazil
Shire
Covance; PRA Health Sciences; PharmaNet

Completed

Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy

Mucopolysaccharidosis II | Hunter Syndrome | MPS II

Brazil, Poland, Taiwan
Medtronic - MITG

Terminated

Clinical Management With SPM System and Validation of the SPM 5 Hour Cutoff in Patients With Symptoms of Gastroparesis

Gastroparesis

United States
Masonic Cancer Center, University of Minnesota

Recruiting

Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.

Mucopolysaccharidosis Type I | Hematopoietic Cell Transplantation

United States
REGENXBIO Inc.

Withdrawn

Mucopolysaccharidosis Type II Observational

Mucopolysaccharidosis II

United States, Canada
Green Cross Corporation

Completed

To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients

Mucopolysaccharidosis II

Korea, Republic of
University of Minnesota
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Completed

Neurobehavioral Phenotypes in MPS III

Hurler Syndrome | Sanfilippo Syndrome Type A | Sanfilippo Syndrome Type B

United States
Shire

Terminated

Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)

Mucopolysaccharidosis (MPS)

United States, Canada, United Kingdom, Turkey, Italy, Mexico, Spain
Masonic Cancer Center, University of Minnesota

Withdrawn

MT2018-18: Sleeping Beauty Transposon-Engineered Plasmablasts for Hurler Syndrome Post Allo HSCT

Mucopolysaccharidosis Type IH | Mucopolysaccharidosis Type IH (MPS IH, Hurler Syndrome) | MPS IH, Hurler Syndrome
Masonic Cancer Center, University of Minnesota

Completed

Administration of IV Laronidase Post Bone Marrow Transplant in Hurler

Hurler Syndrome

United States
Lallemand Health Solutions
Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

Completed

The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health (MPS)

Menopause

United States
Istanbul Bilgi University

Unknown

Kinesio Tape in the Treatment of Medial Plica Syndrome

Medial Plica Syndrome

Turkey
Zagazig University

Unknown

Second Trimester Pregnancy Termination in Women With Previous Caesarean Sections

Second Trimester Abortion

Egypt

Search clinical trials for: Mucopolysaccharidosis (mps) 2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations